drugset / Trial / NCT06889857

Safety and Efficacy of Intravenous Administration of SHED-CM for ALS

NCT06889857 ↗

Phase 0 Active not recruiting 10 enrolled Hitonowa Medical U-Factor Co.,Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety and efficacy of Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media (SHED-CM) in patients with Amyotrophic Lateral Sclerosis (ALS), using the Japanese version of the revised ALS Functional Rating Scale (ALSFRS-R) as an indicator.

Timeline

Start
2024-04-05
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SHED-CM Unknown 120 ml Intravenous